Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Insulin Glargine (Lantus) vs PT-141 (Bremelanotide)
An educational, source-based comparison of Insulin Glargine (Lantus) and PT-141 (Bremelanotide) — how each peptide works, what it's researched for, and what to know before going deeper.
Long-acting basal insulin analog for type 1 and type 2 diabetes.
Recombinant human insulin analog with two arginine residues added to the B-chain and asparagine→glycine at A21, forming microprecipitates at injection site for ~24-hour glucose-lowering activity via insulin receptor activation.
- Type 1 diabetes basal coverage
- Type 2 diabetes basal insulin therapy
- Gestational diabetes
- • FDA-approved.
- • Hypoglycemia and weight gain are primary risks.
- • Do not mix with other insulins.
Melanocortin agonist researched for sexual desire and arousal.
A synthetic analog of α-MSH that activates melanocortin receptors (primarily MC4R) in the central nervous system. Unlike PDE5 inhibitors, it acts on neural pathways governing sexual desire rather than vascular flow.
- Hypoactive sexual desire disorder (FDA-approved as Vyleesi in premenopausal women)
- Male erectile response (research)
- Central arousal pathways
- • FDA-approved (Vyleesi) only for HSDD in premenopausal women.
- • Can cause nausea, flushing, transient blood pressure increases.
- • Avoid in uncontrolled hypertension or cardiovascular disease.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Insulin Glargine (Lantus) | Treat-to-target insulin glargine trials | Diabetes Care | 2003 | Established efficacy and lower nocturnal hypoglycemia vs NPH insulin. |
| PT-141 (Bremelanotide) | Bremelanotide for hypoactive sexual desire disorder | Obstetrics & Gynecology | 2019 | Phase 3 RECONNECT trials supporting FDA approval. |
Side-effect & safety grid
- FDA-approved.
- Hypoglycemia and weight gain are primary risks.
- Do not mix with other insulins.
- FDA-approved (Vyleesi) only for HSDD in premenopausal women.
- Can cause nausea, flushing, transient blood pressure increases.
- Avoid in uncontrolled hypertension or cardiovascular disease.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Insulin Glargine (Lantus) vs PT-141 (Bremelanotide) — Key differences
- Class: Insulin Glargine (Lantus) is classified as Insulin Analog · Endocrine, while PT-141 (Bremelanotide) is Sexual Health · Neurologic.
- Primary research focus: Insulin Glargine (Lantus) — type 1 diabetes basal coverage; PT-141 (Bremelanotide) — hypoactive sexual desire disorder (fda-approved as vyleesi in premenopausal women).
- Tag: FDA-Approved · Diabetes vs Libido.
Insulin Glargine (Lantus) — Frequently Asked Questions
Lantus vs Humalog — what is the difference?+
Lantus (insulin glargine U-100) is a long-acting basal insulin analogue providing a relatively flat 24-hour glucose-lowering profile from a once-daily subcutaneous injection; it is used to cover fasting and between-meal glucose. Humalog (insulin lispro) is a rapid-acting mealtime analogue with an onset of ~15 minutes, peak at ~1 hour, and duration of ~4 hours; it is dosed at meals to cover the postprandial glucose rise. In a basal-bolus regimen the two are used together, not interchangeably.
Lantus vs Novolog — how do they differ?+
Lantus (insulin glargine) is a long-acting basal insulin; Novolog (insulin aspart) is a rapid-acting mealtime insulin. They serve different roles in a basal-bolus regimen — Lantus provides 24-hour background coverage, Novolog covers meals. Novolog is pharmacokinetically similar to Humalog (lispro).
Insulin glargine vs lispro — can they be mixed in the same syringe?+
No. Insulin glargine (Lantus) must not be mixed with any other insulin, including rapid-acting analogues such as lispro (Humalog) or aspart (Novolog). Mixing alters the pharmacokinetic profile of glargine and is contraindicated per FDA labeling. Basal-bolus therapy uses separate injections.
Novolog vs Lantus timing — how are they scheduled?+
Lantus (glargine) is typically dosed once daily at the same time each day (morning or bedtime). Novolog (aspart) is dosed within 5–10 minutes of the start of a meal — sometimes immediately after in specific populations. Splitting basal (Lantus) and mealtime (Novolog) coverage is the standard basal-bolus approach.
PT-141 (Bremelanotide) Research Protocol Table
Structured summary of dosing, routes, and durations as described in published research and FDA labels. Educational reference only — not dosing guidance.
| Context | Population | Route | Dose | Duration | Notes |
|---|---|---|---|---|---|
| Hypoactive sexual desire disorder (HSDD), premenopausal women | Adult premenopausal women (FDA-approved indication) | Subcutaneous autoinjector (abdomen or thigh) | 1.75 mg | On-demand, ≥45 minutes before sexual activity; no more than 1 dose / 24 h, ≤8 doses / month | Reflects the FDA-approved Vyleesi prescribing information for HSDD in premenopausal women. |
| Erectile-response research (men) | Adult men in published Phase II trials | Subcutaneous injection | Ranges of 1.0–6.0 mg studied; commonly cited research dose ~1.75 mg | Single-dose, on-demand within published studies | Not an FDA-approved indication; intranasal PT-141 program in men was discontinued over blood-pressure signals. |
| Off-label exploratory use (general research literature) | Both sexes, varied | Subcutaneous | 0.5–2 mg ranges cited in non-clinical literature | Acute, episodic | Off-label discussion only — no validated long-term protocol exists. |
PT-141 (Bremelanotide) Research — Female vs Male Studies
How published PT-141 (Bremelanotide) research breaks down by sex, including which populations were studied and what trial data exist.
Female research
PT-141 (bremelanotide, brand name Vyleesi) is FDA-approved for hypoactive sexual desire disorder in premenopausal women, supported by the RECONNECT Phase III trials.
- Premenopausal women with acquired, generalized HSDD
- Excluded: postmenopausal women, cardiovascular high-risk subjects
- • Primary endpoints in RECONNECT-1/2 measured change in desire (FSFI-D) and decrease in distress (FSDS-DAO Item 13).
- • Most-reported adverse events: nausea, flushing, headache, injection-site reactions.
- • Transient blood-pressure increases reported; not recommended for women with uncontrolled hypertension or known cardiovascular disease.
Male research
In men, PT-141 has been studied for erectile function but is not FDA-approved. The intranasal development program was discontinued due to blood-pressure concerns; subcutaneous research data remain limited.
- Adult men with erectile dysfunction, including PDE5-inhibitor non-responders, in Phase II research
- • Published erectile-response signals in Phase II trials did not translate into an approved indication.
- • Hypertensive episodes were the principal safety concern that ended intranasal development.
- • Any male use today is off-label; no validated dosing schedule exists for men outside research settings.
PT-141 (Bremelanotide) — Frequently Asked Questions
Is PT-141 FDA-approved for women?+
Yes. Bremelanotide (brand name Vyleesi) is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women, administered as a 1.75 mg subcutaneous autoinjector on demand.
Is PT-141 FDA-approved for men?+
No. PT-141 is not FDA-approved for any indication in men. Earlier intranasal development in men was discontinued because of transient blood-pressure increases observed in trials.
How long does PT-141 take to work?+
Published research and the Vyleesi label describe dosing about 45 minutes before anticipated activity, with effects typically lasting several hours.
What are the most common PT-141 side effects?+
Nausea, flushing, headache and injection-site reactions are most frequently reported. Transient increases in blood pressure and decreases in heart rate have also been documented.
Who should not use PT-141?+
People with uncontrolled hypertension or known cardiovascular disease are advised against PT-141 in the FDA label. It is also not indicated in postmenopausal women, men, or pediatric populations.